Skip to main content

Table 1 Demographics and clinicopathologic features associated with TMA cohort

From: Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness

Variable Median Range
Age at diagnosis (years) 57 36–73
Body mass index 26.54 20.04–39.15
PSA at diagnosis (ng/ml) 5.99 1.29–38
Variable Frequency %
Race
 African American 17 8.5
 Asian 2 1
 Caucasian 173 86.5
 Other 8 4
Family history of prostate cancer
 No 112 56
 Yes 73 36.5
TNM stage
 Local 132 66
 Advanced 68 34
Gleason score
 6 110 55
 7 (3 + 4) 56 28
 7 (4 + 3) 11 5.5
 8 14 7
 9–10 9 4.5
Extraprostatic extension
 No 136 68
 Yes 63 31.5
Lymph node metastases
 No 195 97.5
 Yes 3 1.5
Distant metastasis
 No 165 82.5
 Yes 6 3
Adjuvant therapya
 None 169 84.5
 Adjuvant radiation only 2 1
Chemotherapya
 No 168 84
 Yes 3 1.5
Radiation therapya
 No 160 80
 Yes 11 5.5
Hormonal therapya
 No 160 80
 Yes 12 6
Surgical margin status
 Negative 169 84.5
 Positive 31 15.5
Seminal vesicle involvement
 No 186 93
 Yes 14 7
  1. Numbers do not always add up to 200 (or 100%) in some categories because of cases with missing data
  2. aAll treatment modalities were applied postoperatively